|
US20030044384A1
(en)
*
|
1997-10-09 |
2003-03-06 |
Pro-Virus, Inc. |
Treatment of neoplasms with viruses
|
|
EP1227828A1
(en)
|
1999-11-12 |
2002-08-07 |
Oncolytics Biotech, Inc. |
Viruses for the treatment of cellular proliferative disorders
|
|
AUPQ425699A0
(en)
|
1999-11-25 |
1999-12-23 |
University Of Newcastle Research Associates Limited, The |
A method of treating a malignancy in a subject and a pharmaceutical composition for use in same
|
|
EP1244469A2
(en)
*
|
1999-12-08 |
2002-10-02 |
Onyx Pharmaceuticals, Inc. |
Mutant simplex virus for treating unwanted hyperproliferative cell growth
|
|
US8491884B2
(en)
|
2000-05-03 |
2013-07-23 |
Oncolytics Biotech Inc. |
Virus clearance of neoplastic cells from mixed cellular compositions
|
|
AR028039A1
(es)
|
2000-05-03 |
2003-04-23 |
Oncolytics Biotech Inc |
Remocion de reovirus de celulas neoplasticas intermediadas por ras a partir de composiciones celulares mixtas
|
|
AR028040A1
(es)
*
|
2000-05-03 |
2003-04-23 |
Oncolytics Biotech Inc |
Remocion de virus de celulas neoplasticas a partir de composiciones celulares mixtas
|
|
US7306902B2
(en)
|
2002-06-28 |
2007-12-11 |
Oncolyties Biotech Inc. |
Oncolytic viruses as phenotyping agents for neoplasms
|
|
US20050013803A1
(en)
*
|
2000-07-07 |
2005-01-20 |
Benjamin Thomas L. |
Diagnosing and treating cancer cells using mutant viruses
|
|
US20020147996A1
(en)
*
|
2000-07-07 |
2002-10-10 |
Benjamin Thomas L. |
Diagnosing and treating cancer cells using Sal2
|
|
US20020156039A1
(en)
*
|
2000-07-07 |
2002-10-24 |
Benjamin Thomas L. |
Diagnosing and treating cancer cells using Sal2
|
|
US20030157481A1
(en)
*
|
2001-12-10 |
2003-08-21 |
Benjamin Thomas L. |
Diagnosing and treating cancer cells using T-HR mutants and their targets
|
|
AR035227A1
(es)
*
|
2001-02-20 |
2004-05-05 |
Oncolytics Biotech Inc |
Uso de un agente quimioterapeutico para la manufactura de un medicamento para la sensibilizacion de celulas neoplasicas resistentes a agentes quimioterapeuticos con reovirus
|
|
WO2003050135A2
(en)
*
|
2001-12-07 |
2003-06-19 |
Board Of Regents The University Of Texas System |
Use a parapox b2l protein to modify immune responses to administered antigens
|
|
JP2005526099A
(ja)
*
|
2002-03-26 |
2005-09-02 |
オンコリティクス バイオテック， インコーポレイティッド |
癌治療のための、ｖａ遺伝子が変異したアデノウイルスの使用
|
|
CA2483551A1
(en)
*
|
2002-04-26 |
2003-11-06 |
Wellstat Biologics Corporation |
Immunogenic agent therapy using plasmapheresis or exchange transfusion
|
|
US20040180438A1
(en)
*
|
2002-04-26 |
2004-09-16 |
Pachuk Catherine J. |
Methods and compositions for silencing genes without inducing toxicity
|
|
WO2004009763A2
(en)
|
2002-07-24 |
2004-01-29 |
Arizona Board Of Regents |
Use of vaccinia virus deleted for the e3l gene as a vaccine vector
|
|
EP1578396A4
(en)
|
2002-08-12 |
2007-01-17 |
David Kirn |
METHODS AND COMPOSITIONS RELATING TO POXVIRUS AND CANCER
|
|
AU2002953436A0
(en)
|
2002-12-18 |
2003-01-09 |
The University Of Newcastle Research Associates Limited |
A method of treating a malignancy in a subject via direct picornaviral-mediated oncolysis
|
|
BRPI0411526A
(pt)
|
2003-06-18 |
2006-08-01 |
Genelux Corp |
vìrus de vaccinia e outros microrganismos recombinates modificados e usos dos mesmos
|
|
EP1648233A4
(en)
*
|
2003-07-08 |
2006-08-23 |
Univ Arizona |
VACCINE VACCINE MUTANTS INSTEAD OF ONCOLYTIC AGENTS
|
|
US7442372B2
(en)
|
2003-08-29 |
2008-10-28 |
Biomarin Pharmaceutical Inc. |
Delivery of therapeutic compounds to the brain and other tissues
|
|
US7429481B2
(en)
*
|
2004-09-14 |
2008-09-30 |
University Of Pittsburgh |
Targeting viruses using a modified sindbis glycoprotein
|
|
WO2006071966A2
(en)
*
|
2004-12-29 |
2006-07-06 |
The Brigham And Women's Hospital, Inc. |
Rapamycin compounds in the treatment of neurofibromatosis type 1
|
|
BRPI0608310A2
(pt)
*
|
2005-02-23 |
2009-12-08 |
Bavarian Nordic As |
uso de um poxvìrus modificado para a indução rápida de imunidade contra um poxvìrus ou outros agentes infecciosos
|
|
CN101137748B
(zh)
*
|
2005-03-07 |
2011-12-14 |
罗巴斯研究机构 |
粘液瘤病毒与雷帕霉素的组合在治疗性处理中的应用
|
|
US20070004767A1
(en)
*
|
2005-06-30 |
2007-01-04 |
Gutmann David H |
Methods for treating neurofibromatosis 1
|
|
CA2617600A1
(en)
|
2005-08-01 |
2007-09-07 |
University Technologies International, Inc. |
Attenuated reovirus
|
|
US10668119B2
(en)
|
2005-08-01 |
2020-06-02 |
Virocure, Inc. |
Attenuated reovirus
|
|
US8980246B2
(en)
|
2005-09-07 |
2015-03-17 |
Sillajen Biotherapeutics, Inc. |
Oncolytic vaccinia virus cancer therapy
|
|
KR101772375B1
(ko)
|
2005-09-07 |
2017-08-29 |
신라젠(주) |
Ｇｍ-ｃｓｆ를 발현하는 폭스바이러스를 사용한 전이성 및/또는 전신 파종성 암의 전신 치료법
|
|
US20070190032A1
(en)
*
|
2006-02-13 |
2007-08-16 |
Oncolytics Biotech Inc. |
Use of Local Immune Suppression to Enhance Oncolytic Viral Therapy
|
|
WO2008100292A2
(en)
|
2006-10-16 |
2008-08-21 |
Genelux Corporation |
Modified vaccinia virus strains for use in diagnostic and therapeutic methods
|
|
US10369171B2
(en)
|
2007-03-13 |
2019-08-06 |
Virocure, Inc. |
Attenuated reoviruses for selection of cell populations
|
|
WO2008156655A2
(en)
|
2007-06-15 |
2008-12-24 |
Genelux Corporation |
Vaccinia virus vectors encoding a sodium-dependent transporter protein for imaging and/or treatment of tumors
|
|
CA2693623A1
(en)
*
|
2007-07-18 |
2009-01-22 |
Genelux Corporation |
Use of a chemotherapeutic agent in the preparation of a medicament for treating or ameliorating an adverse side effect associated with oncolytic viral therapy
|
|
WO2009135614A2
(en)
*
|
2008-05-09 |
2009-11-12 |
Bayer Schering Pharma Aktiengesellschaft |
Use of a virus regimen for the treatment of diseases
|
|
WO2009139921A2
(en)
*
|
2008-05-16 |
2009-11-19 |
Genelux Corporation |
Microorganisms for preventing and treating neoplasms accompanying cellular therapy
|
|
US20110086005A1
(en)
*
|
2008-05-27 |
2011-04-14 |
Oncolytics Biotech Inc. |
Modulating interstitial pressure and oncolytic viral delivery and distribution
|
|
CA2937492C
(en)
|
2008-11-11 |
2019-08-13 |
The Board Of Regents Of The University Of Texas System |
Inhibition of mammalian target of rapamycin
|
|
ES2848650T3
(es)
|
2009-09-14 |
2021-08-11 |
Sillajen Biotherapeutics Inc |
Terapia combinada contra el cáncer con virus vaccinia oncolítico
|
|
US9283211B1
(en)
|
2009-11-11 |
2016-03-15 |
Rapamycin Holdings, Llc |
Oral rapamycin preparation and use for stomatitis
|
|
BR112013017096A2
(pt)
|
2011-01-04 |
2020-09-01 |
Jennerex Inc. |
composição e métodos de indução de resposta citotóxica dependente de complemento mediado por anticorpo específico de tumor em animal tendo tumor, de geração de anticorpos in vivo, de inibição do crescimento ou morte de célula de câncer, para tratar indivíduo com câncer, para adaptar de terapia de câncer para indivíduo com câncer e para identificar antígeno específico de tumor
|
|
WO2012122649A1
(en)
*
|
2011-03-15 |
2012-09-20 |
Ottawa Hospital Research Institute |
Recombinant orf virus
|
|
JP6415977B2
(ja)
|
2011-04-15 |
2018-10-31 |
ジェネラックス・コーポレイションＧｅｎｅｌｕｘ Ｃｏｒｐｏｒａｔｉｏｎ |
弱毒化ワクシニアウイルスのクローン株およびその使用方法
|
|
WO2013052915A2
(en)
|
2011-10-05 |
2013-04-11 |
Genelux Corporation |
Method for detecting replication or colonization of a biological therapeutic
|
|
WO2014160328A1
(en)
|
2013-03-13 |
2014-10-02 |
The Board Of Regents Of The University Of Texas System |
Mtor inhibitors for prevention of intestinal polyp growth
|
|
EP2971008B1
(en)
|
2013-03-14 |
2018-07-25 |
Salk Institute for Biological Studies |
Oncolytic adenovirus compositions
|
|
DE102013105144A1
(de)
*
|
2013-05-17 |
2014-11-20 |
Arno Thaller |
Pharmazeutisches Kombinationspräparat mit einem anti-idiotypischen Antikörperfragment
|
|
US9700544B2
(en)
|
2013-12-31 |
2017-07-11 |
Neal K Vail |
Oral rapamycin nanoparticle preparations
|
|
AU2014373683B2
(en)
|
2013-12-31 |
2020-05-07 |
Rapamycin Holdings, Llc |
Oral rapamycin nanoparticle preparations and use
|
|
ES2841075T3
(es)
|
2014-10-24 |
2021-07-07 |
Calidi Biotherapeutics Inc |
Enfoque de inmunoterapia de combinación para el tratamiento del cáncer
|
|
CN107735103B
(zh)
|
2015-02-25 |
2022-05-27 |
纪念斯隆-凯特琳癌症中心 |
使用灭活的非复制型的修饰的痘苗病毒安卡拉(mva)作为实体肿瘤的单一免疫疗法或与免疫检查点阻断剂的组合
|
|
CN116173193A
(zh)
|
2015-04-17 |
2023-05-30 |
纪念斯隆凯特琳癌症中心 |
Mva或mvaδe3l作为抗实体瘤的免疫治疗剂的应用
|
|
KR102201147B1
(ko)
|
2015-08-11 |
2021-01-11 |
카리디 바이오테라퓨틱스, 인크. |
암 치료에 사용하기 위한 천연두 백신
|
|
BR112018013930A2
(pt)
|
2016-01-08 |
2018-12-11 |
Replimune Limited |
vírus oncolítico, vírus que expressa três genes heterólogos, composição farmacêutica, vírus para o uso, produto de fabricação, método de tratamento de câncer e uso do vírus
|
|
CN105754952B
(zh)
*
|
2016-02-16 |
2020-07-10 |
中国农业科学院兰州兽医研究所 |
抗羊痘病毒k3l蛋白c末端的单克隆抗体及其应用
|
|
CA3013637A1
(en)
|
2016-02-23 |
2017-08-31 |
Salk Institute For Biological Studies |
High throughput assay for measuring adenovirus replication kinetics
|
|
JP7015551B2
(ja)
|
2016-02-23 |
2022-02-15 |
ソーク インスティテュート フォー バイオロジカル スタディーズ |
ウイルス動態への影響を最小限にするための治療用アデノウイルスにおける外因性遺伝子発現
|
|
AU2017222686B2
(en)
|
2016-02-25 |
2021-12-23 |
Memorial Sloan Kettering Cancer Center |
Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human Flt3L or GM-CSF for cancer immunotherapy
|
|
IL261321B2
(en)
|
2016-02-25 |
2023-12-01 |
Memorial Sloan Kettering Cancer Center |
Recombinant MVA or MVADELE3L expressing human FLT3L and their use as immunotherapeutic agents against solid tumors
|
|
US20200316146A1
(en)
*
|
2016-03-25 |
2020-10-08 |
University Of Pittsburgh - Of The Commonwealth System Of Higher Education |
Synthetically enveloped virus
|
|
WO2017205674A1
(en)
*
|
2016-05-25 |
2017-11-30 |
Arizona Board Of Regents On Behalf Of Arizona State University |
Oncolytic vaccinia virus mutants and using same for cancer treatment
|
|
WO2018016917A1
(ko)
*
|
2016-07-21 |
2018-01-25 |
코오롱생명과학 주식회사 |
재조합 백시니아 바이러스 및 이의 용도
|
|
CN110062630A
(zh)
|
2016-12-12 |
2019-07-26 |
萨克生物研究学院 |
肿瘤靶向合成腺病毒及其用途
|
|
WO2018209315A1
(en)
|
2017-05-12 |
2018-11-15 |
Memorial Sloan Kettering Cancer Center |
Vaccinia virus mutants useful for cancer immunotherapy
|
|
US10610583B2
(en)
|
2017-08-31 |
2020-04-07 |
Regents Of The University Of Minnesota |
Methods and compositions for treating glioma and medulloblastoma brain tumors using the zika virus
|
|
KR102267837B1
(ko)
*
|
2018-01-19 |
2021-06-22 |
코오롱생명과학 주식회사 |
재조합 백시니아 바이러스 및 이를 포함하는 약학 조성물
|
|
US11505782B2
(en)
|
2018-06-04 |
2022-11-22 |
Calidi Biotherapeutics, Inc. |
Cell-based vehicles for potentiation of viral therapy
|
